Clinical trials located in

Villeurbanne

Villeurbanne city is located in France. Currently, 6 clinical trials are being conducted in this city.

Villeurbanne, nestled in France’s Auvergne-Rhône-Alpes region, stands out as Lyon’s vibrant neighbor. Established in 1349, this city boasts a rich tapestry of history and modernity. Home to the renowned National Institute of Applied Sciences (INSA), Villeurbanne is a hub for education and innovation. The city’s cultural heartbeat is palpable at the TNP (Théâtre National Populaire), emphasizing its commitment to accessible art. Villeurbanne’s architectural marvel, the Gratte-Ciel (Skyscrapers) district, showcases urban planning and Art Deco elegance from the 1930s, reflecting its forward-thinking spirit.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Studying safety & efficacy of new drug for early Alzheimer’s

    This study involves a new drug called AL-101(Alector) (GSK4527226). It is intended for people suffering from the early stage of Alzheimer’s disease. We will give some people with Alzheimer’s disease a drug and others a neutral drug (placebo). Scientists want to see if the new drug is better. Doctors use scoring systems to check a drug’s effectiveness. One way is through the CDR-SB score, which tests things like memory or problem-solving. Patients must score from 0 to 18 points. Higher scores mean they have more difficulties. Another way to check it is iADRS – it is a composite score that measures cognitive properties and functions. It is a combination of two tests called ADAS-Cog14 and ADCS-iADL. They test your thinking ability and ability to perform everyday activities. Higher scores mean they have more problems. Doctors also use ADAS-Cog14, ADCS-ADL-MCI, and ADCS-iADL separately to check for the same things, and ADCOMS to see how brain function changes over time.

    • AL-101(Alector)/GSK4527226
  • Study of the effects of Durvalumab and Domvanalimab on non-small cell lung cancer

    This study looks at two drugs – Durvalumab and Domvanalimab – and how they may help people with a type of lung cancer that cannot be removed by surgery. These medicines are given to patients after special treatment combining chemotherapy and radiotherapy. The goal is to find out whether these drugs provide benefits and are safe to use. During the trial, patients will be given the real drug or a placebo (a substance that has no therapeutic effect), without knowing which one they will receive. The study will measure how long it takes for the disease to worsen, how long people live and how many people respond positively to treatment. This clinical trial is testing the effectiveness of Durvalumab and Domvanalimab – two drugs – in the treatment of stage III lung cancer that cannot be surgically removed. After undergoing chemotherapy and radiation therapy, participants will be given these drugs to assess their safety. The study is double-blind, meaning neither participants nor researchers know who is receiving the actual drug and who is receiving the placebo. The study will monitor whether the cancer gets worse and what the rate of positive reactions to the drugs is. A study is being conducted with two drugs, Durvalumab and Domvanalimab, for patients with advanced forms of lung cancer that cannot be treated with surgery. After undergoing combined chemotherapy and radiation therapy, participants receive these drugs. The study was designed so that neither the patient nor the doctor knew whether the correct drug or a placebo was being administered. The time until the disease worsens, how long participants live and the number of patients who see improvement with the drugs will be measured.

    • Domvanalimab
    • Durvalumab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in France:

.